Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069

Summary

Study to investigate relative bioavailability of up to five different formulations of AZD5069

Timeline

Start

2014-01

Primary completion

2014-04

Completion

2014-04

Publications

• Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wahlby Hamren U, Wray H. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. Drugs R D. 2018 Jun;18(2):149-159. doi: 10.1007/s40268-018-0236-x.

Drugs

Indications